Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.

Durability metrics included median duration of response 29.1 months and median PFS 30.2 months, with ongoing responses ...

Puma Biotechnology has launched the phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202; NCT07465757) evaluating the investigational ...

The FDA has accepted a supplemental new drug application and granted priority review to elinzanetant (Lynkuet) for moderate ...

Trispecific T-cell engagers target two tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.

Jeffrey V. Matous, MD, discusses moving fixed-duration T-cell–redirecting therapy into frontline multiple myeloma treatment ...

C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.

The FDA has approved the kinase inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally ...

Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that ...

FDA recommended a new survival-confirmatory trial prior to BLA submission, despite statistically significant ORR and PFS ...

Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings. The 23rd International Myeloma Society ...

Cure is defined as 5 years in complete remission without any anti-myeloma therapy, timed from treatment end rather than from initial response while still on treatment. Eligibility requires ≥4 ...